Tablet-Based Sensor: A Stable and User-Friendly Tool for Point-of-Care Detection of Glucose in Urine.

Biosensors (Basel)

Department of Chemical and Materials Engineering, Gina Cody School of Engineering, Concordia University, Montreal, QC H3G 2W1, Canada.

Published: September 2023

The colorimetric detection of glucose in urine through enzymatic reactions offers a low-cost and non-invasive method to aid in diabetes management. Nonetheless, the vulnerability of enzymes to environmental conditions, particularly elevated temperatures, and their activity loss pose significant challenges for transportation and storage. In this work, we developed a stable and portable tablet sensor as a user-friendly platform for glucose monitoring. This innovative device encapsulates glucose oxidase and horseradish peroxidase enzymes with dextran, transforming them into solid tablets and ensuring enhanced stability and practicality. The enzymatic tablet-based sensor detected glucose in urine samples within 5 min, using 3,3',5,5'-tetramethylbenzidine (TMB) as the indicator. The tablet sensor exhibited responsive performance within the clinically relevant range of 0-6 mM glucose, with a limit of detection of 0.013 mM. Furthermore, the tablets detected glucose in spiked real human urine samples, without pre-processing, with high precision. Additionally, with regard to thermal stability, the enzyme tablets better maintained their activity at an elevated temperature as high as 60 °C compared to the solution-phase enzymes, demonstrating the enhanced stability of the enzymes under harsh conditions. The availability of these stable and portable tablet sensors will greatly ease the transportation and application of glucose sensors, enhancing the accessibility of glucose monitoring, particularly in resource-limited settings.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526991PMC
http://dx.doi.org/10.3390/bios13090893DOI Listing

Publication Analysis

Top Keywords

glucose urine
12
glucose
9
tablet-based sensor
8
detection glucose
8
stable portable
8
portable tablet
8
tablet sensor
8
glucose monitoring
8
enhanced stability
8
detected glucose
8

Similar Publications

Background: While the associations between pediatric non-obese metabolic dysfunction-associated fatty liver disease (MAFLD) and multiple diagnostic biomarkers are well-established, the role of a broader range of blood-based, urine-based, and body composition-based biomarkers for monitoring MAFLD are needed.

Methods: A pediatric cohort was established in Wuxi, China. We measured body composition biomarkers, blood-based and urine-based biomarkers, and liver stiffness in participants to diagnose MAFLD and identify alternative and novel potential biomarkers for MAFLD.

View Article and Find Full Text PDF

Background And Purpose: Eukaryotic elongation factor 2 kinase (eEF2K) belongs to the Ca/calmodulin-dependent protein kinase family. We previously revealed that A484954, a selective eEF2K inhibitor, caused hypotensive and diuretic effects via the production of nitric oxide (NO) in spontaneously hypertensive rats. Otsuka Long-Evans Tokushima Fatty (OLETF) rats are hypertensive because of obesity and type 2 diabetes.

View Article and Find Full Text PDF

Background: Enhancing self-management in health care through digital tools is a promising strategy to empower patients with type 2 diabetes (T2D) to improve self-care.

Objective: This study evaluates whether the Greenhabit (mobile health [mHealth]) behavioral treatment enhances T2D outcomes compared with standard care.

Methods: A 12-week, parallel, single-blind randomized controlled trial was conducted with 123 participants (62/123, 50%, female; mean age 58.

View Article and Find Full Text PDF

A comprehensive review of the efficacy and safety of ertugliflozin.

Expert Opin Drug Metab Toxicol

January 2025

The First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang, Hunan, China.

Introduction: Ertugliflozin is the fourth sodium-glucose co-transporter (SGLT2) inhibitor approved by the US FDA in 2017 for the treatment of type 2 diabetes mellitus.

Areas Covered: The main purpose of this review is to evaluate the clinical efficacy and safety of ertugliflozin. We conducted a search of relevant literature on ertugliflozin in the PubMed and Web of Science databases up to 22 October 2024.

View Article and Find Full Text PDF

The g-C3N4/CS biosensor was designed, fabricated, and tested using compounds such as glucose, urine, lactose, and flutamide at a molarity of 10 µM, which could demonstrate a high sensitivity of 200 μm-1 for flutamide. Powerful effective medium theory and FDTD simulation were used to predict the most favorable mode and plasmonic properties of a graphite carbon nitride and chitosan nanocomposite. The research also explores the characteristics of surface plasmon resonance exhibited by the nanocomposite as the chitosan content is adjusted.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!